2019 First Quarter Business Highlights and Financial Results

what a travesty of sorts

 

This was before the SF expansion. Issues with prior auth or discounts/chargebacks/returns are probably the issue here. Also, you can't expect a new rep to start being productive right off the bat.

 

Ok then give them a year and they will produce 1 NBRx. yippie!

 

I was productive right off the bat when I first started plus I did not inherit a territory that already had existing prescribers like every expansion rep did. Issues with prior auths, blah blah blah. Just look in the mirror and listen to your own excuses for the failure that you are.

 

“Productive right off the bat”. Liar. OMG! You’re Gods gift to the pharm industry. We are so honored by having you and your self righteous promotion. What would we do without you. Can you teach us how to be just like you? IDIOT!

 

Your ass!

 

Q2 2019
$4.8 million

Revenue from product sales during the three months ended June 30, 2019, were $28.7 million, consistent with the comparable period of 2018. Revenue from RAYALDEE was $5.6 million for the quarter, compared to $4.8 million for the comparable 2018 period.

 

You must factor in the price increases.